For immediate Release
November 06, 2003
Start-ups are advised to understand importance of drug reimbursement
It is important for bioscience companies to work with health
insurance organizations during product development and clinical
trials for new drugs and take into account reimbursement issues
that may affect their ability to penetrate target markets.
Michael Mills, senior manager in government economics for
Amgen, discussed these important reimbursement issues with
a group of local entrepreneurs, scientists and industry affiliates
who attended November’s “Brown Bag” luncheon.
The luncheon, organized by the Virginia Biosciences Development
Center, was sponsored by MPR Associates, Inc.
Virginia BioTechnology Research Park
Phone: (804) 828-6884
Web site: http://www.vabiotech.com